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Abstract
Pancreatic cancer is characterized as a disease with low survival and high mortality because of no effective diagnostic
and therapeutic strategies available in clinic. Conventional clinical diagnostic methods including serum markers and
radiological imaging (CT, MRI, EUS, etc.) often fail to detect precancerous or early stage lesions. Development of
effective biomarkers is unmet for reduction of mortality of pancreatic cancer. MicroRNAs (miRNAs) are a group of
small non-protein-coding RNAs playing roles in regulation of cell physiology including tumorigenesis, apoptotic
escape, proliferation, invasion, epithelial-mesenchymal transition (EMT), metastasis and chemoresistance. Various
altered signaling pathways involving in molecular pathogenesis of pancreatic cancer are mediated by miRNAs as a
role of either oncogenes or tumor suppressors. Among biomarkers developed including protein, metabolites, DNA,
RNA, epigenetic mutation, miRNAs are superior because of its unique chemical property. Recent study suggests that
miRNAs may be promising biomarkers used for early detection of pancreatic cancer. This review will update the
progression made in early detection of pancreatic cancer.
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Background
Pancreatic cancer has an exceptionally low 5-year
survival rate (<5 %) and high mortality rate, making it
the fourth leading cause of cancer mortality in developed
countries [1]. As it is particularly located in an inacces-
sible position of the abdomen leading the common
clinical presentation, greater than 80 % of the affected
patients were diagnosed when occurring locally advan-
cing or metastasis [2]. Thus the early diagnosis of
pancreatic cancer is the key for successful treatment of
the disease, though it is rendered uneasy to accomplish
resulted from the deficiency of early warning signs.
Although much more research into biomarkers has been
investigated, few biomarkers are proven to be effective
used for early diagnosis of the disease [3]. Therefore,
seeking novel biomarkers with higher sensitivity or
specificity is still a challenge.
miRNAs are small non-protein-coding RNAs consis-
ting of 18–24 nucleotides in length involving in regulating
multiple gene expression by degrading target mRNAs or
inhibiting translation at the post-transcriptional level,
thereby regulating various neoplastic processes including
cell proliferation, migration, invasion, survival, and metas-
tasis [4]. Disregulation of miRNA plays an important role
in the pathogenesis, diagnosis and therapy of pancreatic
cancer [3]. Here, we update progression made in miRNA
as early diagnostic/prognostic biomarkers for pancreatic
cancer.
Cancer diagnosis by imaging and biomarkers
Imaging technology has been widely applied as routine
methods in diagnosis, therapy and prognosis of varied
tumor types including pancreatic cancer. Although
common imaging modalities consisting of computed
tomography (CT), magnetic resonance imaging (MRI),
endoscopic ultrasound (EUS), endoscopic retrograde
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cholangiopancreatography (ERCP) have been remarkably
improved in their detection of pancreatic tumor as by
positron emission tomography (PET) or their combi-
nation, sensitivity and specificity of detection of pancreatic
cancer at its early stage remains challenge [5, 6].
As for CA 19-9, widely used biomarker, fails to distin-
guish pancreatic cancer from benign pancreatic diseases
and multiple carcinoma, which limits clinical utility
because of its inadequate sensitivity and specificity
[7]. Similarly, several other serum and tissue-based
biomarkers (Table 1) suffering the same limitation as
CA 19-9, thus none of them have good clinical utility
for early diagnosis of pancreatic cancer [7]. Effective
biomarkers thus coupled with imaging would provide
an ideal approach for early detection of cancer [5].
MicroRNAs as effective biomarkers
Currently, a large sum of studies have identified the
potential role of miRNAs in tumorigenesis and metas-
tasis, suggesting that it may be developed as biomarkers
used for diagnosis, prognosis and prediction of pan-
creatic cancer [8]. Given that miRNA-mediated transcrip-
tional regulation is involved in every cellular process,
abnormal alterations in miRNA expression are commonly
associated with all the carcinogenic process of pancreatic
ductal adenocarcinoma (PDAC), including apoptosis
escape, proliferation, invasion, epithelial-mesenchymal
transition (EMT), metastasis and chemoresistance [8, 9].
Based on their expression, a handful of miRNAs up-
regulated in tumor cells are classified as potent oncogenes,
while some others are classified as tumor suppressors
since they are conversely down-regulated during the
tumorigenesis [10]. MiR-21, for instance, is classified as an
oncogene because whose over-expression is associated
with the increased proliferation, invasion, and chemoresis-
tance of pancreatic cancer cells to Gemcitabine. Like
miR-21, several other miRNAs, which clearly presented
their over-expression in cancer tissues, include miR-155,
miR-106a, miR-27a, miR-221/222, miR-224, miR-486,
miR-194, miR-200b/c, miR-429, miR-10a/b, miR-367,
miR-196a/b, miR-210, miR-375, and miR-301a [9, 10].
Meanwhile, another group of miRNAs showed inhibitory
effects on cell proliferation, invasion and metastasis, thus
functioned as tumor suppressors, including miR-34a/b,
Let-7, miR-96, miR-124, miR-615-5p, miR-200a/b/c,
miR-219-1-3p, miR-203, miR-146a, and miR-17-92 [9, 10].
An interesting study showed that miR-17-92 cluster is
down-regulated in pancreatic cancer stem cells (CSCs),
which showed highly resistant to chemotherapy by activa-
ting NODAL/ACTIVIN/TGF-β1 signaling pathways,
thus, suppression of these pathways may enhance the
sensitivity of pancreatic CSCs to chemotherapy [11].
miRNAs regulate key biological processes of tumor
cells by altering signaling pathways involved in mole-
cular pathogenesis of PDAC, including K-ras, p53,
SMAD4, E-cad, PTEN, ADAM9, Bcl-2, STAT3, Cyclin
D1, EGFR, TGF-β, JNK, Hedgehog, Notch, NF-κB, and
Akt-2 [2]. RAS associated signaling pathways are derived
from the most frequently mutated KRAS in 90 % of
pancreatic cancer, whose translation was found to be
Table 1 Assay parameters of imaging modalities and classical biomarkers used in detection of pancreatic cancer
Item AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) Reference
CT 0.832 92 - 80 67 - [19]
MRI 0.92 100 - 90 100 - [19]
EUS-FNA - 82.1 100 100 79.2 89.4 [20]
MRCP - - - 85 - 80 [21]
ERCP - - - 88 - 85 [21]
MRI+ERCP - - - 91 - 88 [21]
18F-FDGPE/CT 0.759 67.50 72.73 94.74 23.53 68.13 [22]
CA19-9 0.857 75.00 81.82 96.77 31.03 75.82 [22]
18F-FDGPE/CT + CA19-9 0.940 96.25 63.64 95.06 70.00 92.31 [22]
CA125 0.810 78.68 71.05 79.63 51.92 - [23]
CEA 0.670 63.24 63.16 75.44 48.98 -
CA50 0.630 52.21 78.95 81.61 48.00 -
CA724 0.670 65.44 68.42 78.76 52.53 -
CA242 0.640 64.71 60.53 74.58 48.94 -
AFP 0.490 43.38 61.84 67.05 37.90 -
The assay parameters are for diagnosis of differentiation between adenocarcinoma and nonadenocarcinoma. Small liver metastases (0.5 – 1 cm in diameter) were
missed on CT and MRI. Adequate specimens were obtained by EUS-FNAB from 47 of the 50 pancreatic lesions (94.0 %). CA125, CEA, CA50, CA50, CA724, CA242
and AFP are for patients with unresectable pancreatic cancer misjudged as resectable tumor by CT scan. AUC area under the curve, NPV negative predictive value,
PPV positive predictive value, − No data was available in these instances
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Fig. 1 Potential miRNA biomarkers and their associated targeting pathways in pancreatic cancer. ↑ up-regulation ↓ down-regulation
Table 2 The AUC, sensitivity and specificity of miRNA-based biomarkers for detection of pancreatic cancer
Item Drived from AUC Sensitivity (%) Specificity (%) Reference
PCa vs. Normal PCa vs. CP PCa vs. Normal PCa vs. CP PCa vs. Normal PCa vs. CP
miR-20a, 21, 24, 25, 99a, 185, 191 Serum 0.992 89 100 [13]
miR-10b, 155, 106b, 30c, 212 Plasma >0.90 95 100 [14]
Bile 96 100
miR-21, 210, 155, 196a Plasma 0.82 64 89 [15]
CA19-9 Serum 0.903 0.897 81.2 81.2 100.0 89.0 [17]
miR-16, 196a, Plasma 0.895 0.790 87.0 75.4 73.5 66.4
miR-16+miR-196a+CA19-9 - 0.979 0.956 92.0 88.4 95.6 96.3
PaCIC marker Serum - 0.96 0.86 [18]
miR-1246, 4644, 3976, 4306 Serum - 0.81 0.94
PaCIC marker + miR-1246,
4644, 3976, 4306
Serum - 1.00 0.80
Serum miR-20a, 21, 24, 25, 99a, 185 and 191 were derived from 197 PCa cases and 158 age- and sex-matched cancer-free controls. MiR-10b, 155, 106b, 30c and
212 were derived from patients (n = 215) with treatment-naive PDAC (n = 77), CP with bile/pancreatic duct pathology (n = 67), and controls (n = 71). The plasma
levels of miR-21, 210, 155, 196a were interrogated in 49 PCa and 36 normal healthy individuals. Plasma miR-16, 196a and CA19-9 were extracted from 140 PCa
patients, 111 CP patients and 68 normal controls. PaCIC marker and miR-1246, 4644, 3976, 4306 were collected from 20 healthy donors, 131 PCa, 25 CP, 22 benign
pancreatic tumors, 12 nonPCa. PCa pancreatic cancer, CP chronic pancreatitis, AUC area under the curve, − No data was available in the instances
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mediated by miR-96, miR-126, miR-143/145, miR-217
and Let-7 [3]. Recently p53 has been shown to mediate
regulation of miR-34 family (miR-34a/b/c). miRNAs
such as miR-21, miR-143, miR-155, miR-130a/301a/454,
miR-224, miR-146a, miR-483-3p, miR-494, miR-494, and
miR-421 are involved in pancreatic cancer progression
by regulating TGF-β/SMAD-4 signaling either directly
or indirectly [3]. Moreover, miR-137 targets KDM4A
mRNA during Ras-induced senescence, and activates
both p53 and retinoblastoma (pRb) [12]. More informa-
tion about miRNAs as biomarkers and their targeting
pathways are summarized in Fig. 1.
As aberrant expression of miRNA occurs in molecular
pathogenesis of pancreatic cancer, identification of miRNA
signatures differentially expressed in different pathological
stages of the disease may distinguish pancreatic cancer
from pancreatic benign diseases with excellent sensitivity or
specificity. A recent study in serum from patients with
pancreatic cancer demonstrated that seven serum miRNAs,
including miR-20a, miR-21, miR-24, miR-25, miR-99a,
miR-185, miR-191, differentially expressed in pancreatic
cancer compared to cancer-free subjects, suggesting this
miRNA profile may be developed as an effective biomarker
used for early detection of the disease with high sensitivity
and specificity [13]. More study identified a panel of five
miRNAs including miR-10b, −155, −106b, −30c, and −212
in plasma and bile had excellent accuracy, sensitivity, and
specificity for detection of PDAC over the control(patients
with choledocholithiasis but normal pancreata) [14]. Simi-
larly, miR-21, miR-210, miR-155, and miR-196a showed
significant difference in cancer versus healthy control,
further study on miR-21 suggests that this miRNA can be
developed as an independent prognostic biomarker distin-
guishing invasive from non-invasive macroscopic intraduc-
tal papillary mucinous neoplasms (IPMN), which is one of
the precursor lesions of PDAC [15, 16]. It is worth noting
that miRNA biomarkers can play a supplementary role with
several protein markers in early identification of pancreatic
cancer. The combination of a panel of miRNAs, especially
miR-16 and miR-196a with CA19-9, for instance, showed
effective at identification of tumors in Stage 1 [17].
Pancreatic cancer -initiating cell (PaCIC) markers, such as
CD44v6, Tspan8, EpCAM, MET and CD104, combined
with miRNA serum-exosome biomarkers including
miR-1246, miR-4644, miR-3976 and miR-4306, improved
sensitivity significantly with a specificity of 80 % for
pancreatic cancer compared to all others groups [18].
Table 2 lists the sensitivity and the specificity of the
miRNAs mentioned above.
Future perspective
Although more data suggest that miRNAs offers great
potential as biomarkers for early detection of pancreatic
cancer, there are limited prospective validation studies to
prove their efficacy. Most studies thus far have been in
the case-control stage, its application in clinic for predic-
tion and diagnosis of pancreatic cancer at its early stages
remained challenge. This may be due to lack of effective
standard operational procedures (SOPs) used in stan-
dardized clinical assays. Secondarily, no consensus is
agreed about the mechanisms underlying miRNA deregu-
lation in tumor cells, hence understanding better the role
of miRNAs in tumorigensis may eradicate the field of both
molecular diagnosis and effective therapy of pancreatic
cancer.
Conclusions
As gene regulators, miRNAs can regulate cell growth,
differentiation and apoptosis in many cases of human
tumor. Abnormal expression of miRNAs in pancreatic
cancer is the early events of pancreatic cancer develop-
ment, which makes it can be used as a new biological
marker for early detection of pancreatic cancer. Evalu-
ation of single miRNA plays an important role in bio-
marker research, however, a single biomarker is often
limitaed in sensitivity and specificity. A miRNA profile
consists of a panel of up-regulated or down-regulated
miRNAs, thus it can reflect the tumor progression with
high sensitivity and specificity. Although there have been
a large number of literatures which stated the potetial
role of miRNAs as biomarker in pancreatic cnacer early
detection, the application in clinical is still remains to
explore.
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